Sign In
Last checked at 
16 Mar 2015 17:48
For immediate release | 16 March 2015 |
Futura Medical plc
("Futura" or the "Company")
AIM Disclosure
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, has today been informed of the following disclosure in accordance with the requirements of Rule 17 (disclosure of miscellaneous information). On 16 March 2015, administrators were appointed to Hume Capital Securities plc, a company of which Jonathan Freeman, a Non-Executive Director of Futura, was a non-executive director since March 2012.
For any further information please contact:
Futura Medical plc | |
James Barder, Chief Executive | Tel: +44 (0)1483 685 670 |
mail to: james.barder@futuramedical.com | www.futuramedical.com |
N+1 Singer (Nominated Adviser and Broker) | |
Aubrey Powell - Corporate Finance Brough Ransom - Sales
| Tel:+44 (0) 20 7496 3000 |
For media enquiries please contact: | |
Buchanan | |
Mark Court / Sophie Cowles / Stephanie Watson | Tel: +44 (0)20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com
Follow the stocks
